Pharmaceutical

BMS reports 2% revenue loss in 2023 after Revlimid generics hurt sales

Bristol Myers Squibb has reported a 2% revenue decrease from 2022 as it focuses on business development to counteract patent losses.

Feb 2, 2024 - 18:00
BMS reports 2% revenue loss in 2023 after Revlimid generics hurt sales
Bristol Myers Squibb has reported a 2% revenue decrease from 2022 as it focuses on business development to counteract patent losses.
Read the original article

Tags:

Previous Article

We’re naming cancers all wrong, oncology leader says

Next Article

IGC Pharma heads towards a Phase I study for Alzheimer’s disease

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo

Zai Lab and argenx announce NMPA approval for sBLA for ...

Nov 13, 2024

Opinion: Health care coaches are the next big thing. They’re also completely unregulated

Opinion: Health care coaches are the next big thing. Th...

May 9, 2023

Oscotec sees highest patent filings and grants during June in Q2 2024

Oscotec sees highest patent filings and grants during J...

Jul 22, 2024